UK Pharmacy
On this page you will find information for pharmacists involved in the RECOVERY Trial, including FAQs and HRA Pharmacy Assurance.
IMPORTANT NOTICES
June 2024: Please note that current baloxavir supplied for RECOVERY has an expiry date of 30 June 2024. Replacement baloxavir can be ordered now from Roche, but deliveries of this will be delayed until the second half of July. This means that patients should not be randomised to the baloxavir comparison from 28th June until replacement baloxavir has been received.
February 2024: RECOVERY trial sotrovimab has received a further expiry date extension, to 48 months. Note the the sotrovimab comparison is due to close on 31 March 2024, so this only affects sites holding batch 2T8F (which had a previous expiry date of 29 Februrary 2024).
July 2023: RECOVERY trial sotrovimab has received a further expiry date extension, to 36 months. This will require relabelling existing stock. Please see sotrovimab 36 month expiry documents below.
June 2023: Following the closing of the molnupiravir and Paxlovid arms, sites should return any unused study drug to the site pharmacy for general use, following their local guidelines.